Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025)

"Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."
Michael DeMarco, PhD

by Michael DeMarco, PhD

New and emerging pharmacologic treatments for MDD - PubMed
Major depressive disorder (MDD) presents a significant global health challenge, characterized by a high prevalence and significant impact on quality of life. Traditional antidepressants fall short in terms of efficacy and onset speed, up to 60% of patients. This review delves into the new and emergi …
PubMedAslihan Uyar

(2025): New and emerging treatments in MDD have centered on different neurobiological pathways than the traditional monoaminergic systems. Ketamine and its enantiomer, S-ketamine, have been highlighted for their rapid antidepressant effects, which act through non-competitive N-methyl-d-aspartate (NMDA) receptor antagonism and other pathways involving synaptic plasticity.

More like this

Is ketamine a "psychedelic"?

Yes.
Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)

Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)

"These findings demonstrate robust antidepressive activity from a single 25 mg dose of psilocybin combined with psychotherapy and suggest a potentially paradigm-changing alternative to traditional antidepressants requiring further study."

Spotlight: UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia (Aggarwal, et al, 2025)

"The study demonstrated improvements in subjective sleep quality and other captured PROMs in insomnia patients treated with cannabis-based medicinal products."

Spotlight: A Preliminary Approach to Oral Low-Dose Ketamine Self-Administration in Mice (Mus musculus) (Rocha, et al, 2025)

"No significant alterations were observed in liver and kidney function in either sex, nor in inflammation, apoptosis, or DNA damage in kidney tissues. Overall, these findings support the viability of voluntary oral ketamine administration and accentuate the need to refine the proposed model"
Spotlight: PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx™), Aligned with FDA’s CNPV National Priority Initiative

Spotlight: PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx™), Aligned with FDA’s CNPV National Priority Initiative

"The ketamine patch has been in development for several years and is designed to deliver controlled, sustained analgesia for both acute postoperative pain and chronic pain conditions, enabling adoption in hospital, outpatient, and home-care settings."

Spotlight: Ketamine Reverses Chronic Stress-Induced Behavioral Changes via the Expression of Ca2+-Permeable AMPA Receptors in Mice (Flowers, et al, 2025)

"Our findings suggest that subanesthetic low-dose ketamine rapidly triggers the expression of CP-AMPARs in the hippocampus, which induces antidepressant and antistress effects."
Mastodon Mastodon